← Leaderboards
Enrica Marchi
University Of Virginia
$1,212,285
Attributed
$2,424,569
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $808.7K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
FDA$2,424,569 · 1
By mechanism
R01$2,424,569 · 1
Top collaborators
- Owen A O''Connor3 shared
Grant awards (3)
A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin versus Investigator's Choice in Patients with Relapse or Refractory Periperal T-cell lymphoma (PTCL).$808,684
R01 · FY2025 · FD
A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin versus Investigator's Choice in Patients with Relapse or Refractory Periperal T-cell lymphoma (PTCL).$808,153
R01 · FY2022 · FD
A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin versus Investigator's Choice in Patients with Relapse or Refractory Periperal T-cell lymphoma (PTCL).$807,732
R01 · FY2020 · FD